Taurolidine structure
|
Common Name | Taurolidine | ||
---|---|---|---|---|
CAS Number | 19388-87-5 | Molecular Weight | 284.356 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | 471.2±55.0 °C at 760 mmHg | |
Molecular Formula | C7H16N4O4S2 | Melting Point | 156ºC | |
MSDS | USA | Flash Point | 238.8±31.5 °C |
Use of TaurolidineTaurolidine is a broad-spectrum antimicrobial for the prevention of central venous catheter-related infections. Taurolidine has a direct and selective antineoplastic effect on brain tumor cells by the induction of apoptosis[1]. |
Name | Taurolidine |
---|---|
Synonym | More Synonyms |
Description | Taurolidine is a broad-spectrum antimicrobial for the prevention of central venous catheter-related infections. Taurolidine has a direct and selective antineoplastic effect on brain tumor cells by the induction of apoptosis[1]. |
---|---|
Related Catalog | |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 471.2±55.0 °C at 760 mmHg |
Melting Point | 156ºC |
Molecular Formula | C7H16N4O4S2 |
Molecular Weight | 284.356 |
Flash Point | 238.8±31.5 °C |
Exact Mass | 284.061310 |
PSA | 115.58000 |
LogP | -2.55 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.564 |
RIDADR | NONH for all modes of transport |
---|---|
HS Code | 2933990090 |
~72% Taurolidine CAS#:19388-87-5 |
Literature: BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.; Pullagurla, Manik Reddy; Rangisetty, Jagadeesh Babu; Dokula, Neelam Naidu Patent: US2013/237700 A1, 2013 ; Location in patent: Paragraph 0028 ; |
Precursor 2 | |
---|---|
DownStream 1 | |
HS Code | 2933990090 |
---|---|
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.
Int. J. Colorectal Dis. 29(11) , 1339-48, (2014) The taurine derivative taurolidine (TRD) exerts anti-neoplastic effects in a variety of tumor models. On the other hand, TRD at low doses was shown to reduce cell-cell adhesion, a prerequisite for met... |
|
Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.
Pediatr. Blood Cancer 60(8) , 1292-8, (2013) To determine if the catheter lock taurolidine can reduce the number of catheter-related bloodstream infections (CRBSI) in pediatric cancer patients with tunneled central venous catheters (CVC).During ... |
|
Taurolidine specifically inhibits growth of neuroblastoma cell lines in vitro.
J. Pediatr. Hematol. Oncol. 36(4) , e219-23, (2014) Neuroblastoma is a common pediatric solid tumor with poor outcome for metastatic disease. Thus, novel therapeutic options are of main interest. The anti-neoplastic properties of taurolidine have been ... |
4,4'-Methylenebis(tetrahydro-1,2,4-thiadiazine) 1,1,1',1'-tetraoxide |
4,4'-methanediylbis(1,2,4-thiadiazinane) 1,1,1',1'-tetraoxide |
2H-1,2,4-Thiadiazine, 4,4'-methylenebis[tetrahydro-, 1,1,1',1'-tetraoxide |
4,4'-Methylenebis(tetrahydro-1,2,4-sulfadiazine 1,1-dioxide) |
4,4'-Methylenebis(perhydro-1,2,4-thiadiazine 1,1-dioxide) |
Bis(1,1-dioxoperhydro-1,2,4-thiadiazin-4-yl)methane |
4,4'-Methylenebis(1,2,4-thiadiazinane) 1,1,1',1'-tetraoxide |
Taurolin |
Taurolidine |
Tauroline |